Features of diagnosis and antibacterial therapy of community-acquired pneumonia caused by Mycoplasma pneumoniae in children in 2024

Background. DIn 2024, there is a marked increase in cases of mycoplasma community-acquired pneumonia in children. Some studies show that the prevalence of infection caused partly by Mycoplasma pneumoniae, which is antibiotic-resistant to macrolides, has increased by 30% compared to previous years. This increase may be associated with the widespread use of antibiotics such as macrolides (azithromycin and clarithromycin) in the context of the COVID-19 pandemic. Mycoplasma infection caused by Mycoplasma pneumoniae remains one of the urgent problems of pediatrics, especially in the context of growing antibiotic resistance and a changing climate of infectious diseases. An increase in the number of cases of mycoplasma community-acquired pneumonia is recorded every year, which requires more careful attention to this problem from the medical community. With an increase in the number of cases of mycoplasma infection, the spread of antibiotic-resistant strains is also observed. This creates serious problems for treatment, as standard antibacterial drugs become less effective. Studies show that resistance to macrolides, which have traditionally been used to treat this infection, has increased by 15-20% in two years. Symptoms of mycoplasma infection, such as cough, fever and fatigue, often overlap with other acute respiratory diseases. This creates difficulties for doctors in early diagnosis.

Objective. The purpose of the work was to determine the features of the spread and diagnosis of mycoplasma community-acquired pneumonia in children.

Conclusion. The problem of the spread and diagnosis of mycoplasma infection in children in 2024 requires close study and active action by the medical community. The growing level of antibiotic resistance and morbidity, erased clinical symptoms cause difficulty in the differential diagnosis of pneumonia and lead to improved awareness of doctors on mycoplasma community-acquired pneumonia issues.

1. Smirnov A. I., Romanov S. V., Dolgova O. I. Trends in the incidence of mycoplasma pneumonia in children. Zhurnal pediatrii. 2023; 45 (2): 134-140. (In Russ.)

2. Nesterenko Z. V., Prokopyeva N. E., Matalygina O. A., et al. Community-acquired pneumonia in children during the coronavirus epidemic. Meditsina: teoriya i praktika. 2021; 4 (6): 12-20. EDN HPPRGM. (In Russ.)

3. Koshkarina E. A., Strazhnova O. A., Sharabakina M. A., et al. Epidemiological features of mycoplasma pneumonia. Fundamentalnaya i klinicheskaya meditsina. 2021; 3 (6): 85-93. DOI 10.23946/2500-0764-2021-6-3-85-93. EDNOVZZQW. (In Russ.)

4. Petrova T. N., Kovalev G. V., Larina N. M. Antibiotic resistance of Mycoplasma pneumoniae: problems and solutions. Problemy infektsionnykh boleznei. 2024; 102 (1): 55-63. (In Russ.)

5. Mycoplasma pneumoniae and other Mycoplasma species infections. Red Book: 2018. Report of the Committee on Infection Diseases. 31th ed., Ed. Kimberlin D. W., Brady M. T., Jackson M. A., Long S. S. Itasca, IL: American Academy of Pediatrics; 2018: 573-575. Available at: https://redbook.solutions.aap.org/chapter.aspx?sectionid=189640137&bookid=2205.

6. Starkova L. A., Filatova E. N. Modern methods of diagnosing mycoplasma infection. Sovremennye problemy meditsiny. 2024; 13 (3): 202-209. (In Russ.)

7. Kim H. S., Sol I. S., Li D. Efficacy of glucocorticoids for the treatment of macrolide refractory mycoplasma pneumonia in children: meta-analysis of randomized controlled trials. BMC Pulm Med. 2019; 19 (1): 251. (In Russ.)

8. Romanovskaya O. F., Romanova O. N., Legkaya L. A. Mycoplasma pneumonia in children. Zdravookhranenie (Minsk). 2019; 4: 20-28. (In Russ.)

9. Skachkova M. A., Tarasenko N. F., Karpova E. G., Rybalkina M. G. Clinical manifestations of mycoplasma pneumonia in children. Infektsii i vaktsinoprofilaktika. 2021; 10: 315-316. (In Russ.).